Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
| Ticker |
Sentiment |
Impact |
|
COO
|
Neutral
|
4 %
|
|
IRWD
|
Neutral
|
4 %
|
|
OGN
|
Neutral
|
4 %
|
|
VTRS
|
Neutral
|
4 %
|
|
ALC
|
Neutral
|
4 %
|
|
BLCO
|
Somewhat Bullish
|
60 %
|
|
GS
|
Neutral
|
4 %
|
|
INMD
|
Neutral
|
7 %
|
